Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Journal of Translational Medicine|April 13, 2018
Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinibChun-Wei Xu, Wen-Xian Wang, Yan-Ping Chen, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|November 27, 2010
[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]Jinwan Wang, Yan Sun, Yongyu Liu, et al.
Cancer Communications (London, England)|June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyXuezhi Hao, Lin Wang, Yanrong Hao, et al.
Signal Transduction and Targeted Therapy|January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Jian Fang, Xuezhi Hao, et al.
The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 23, 2016
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer]Binghe Xu, Fuguo Tian, Jingrui Yu, et al.
Journal of Hematology & Oncology|April 17, 2020
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter studyChang Lu, Xiao-Rong Dong, Jun Zhao, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
Signal Transduction and Targeted Therapy|June 29, 2023
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II TrialShun Lu, Hongming Pan, Lin Wu, et al.
Pageof 10